^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition

Published date:
04/25/2023
Excerpt:
We performed a phase I/II study to determine the safety and efficacy of CSF1 inhibition with MCS110 in combination with BRAF/MEK inhibition with dabrafenib/trametinib in patients with BRAF V600E/K mutant metastatic melanoma….One patient had a partial response (PR) by RECIST 1.1, one patient had stable disease (SD), 3 patients had disease progression (PD)....One response was observed in this small sample of patients suggesting this combination might be worthy of further exploration.
DOI:
10.1007/s10637-023-01364-5